CTLA4 and neoplasm: This design not only retains the efficacy of combined treatment with PD-1 and CTLA-4 inhibitors but also optimizes the Fc region to eliminate antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) effects, which reduce immune-related adverse reactions and improving stability and anti-tumor activity.